About Von Willebrand Disease — What is VWD
The Humate-P® Difference: High Quality & Quantity

How Clotting Works
Efficacy
Safety
Convenience
Home Infusion Video
Mix2Vial™ Needle-Free transfer Device
The CSL Behring Commitment
Resources and Tools
News & Events
Important Safety Information
Prescribing Information
Request More Information
For Healthcare Professionals
      

Efficacy

Humate-P® is effective for bleeding episodes in all types of VWD.1

Number of bleeding episodes by desease type

A retrospective review of clinical safety and efficacy data obtained from 97 Canadian subjects showed Humate-P® to be effective for bleeding episodes in patients with all types of VWD1:

  • Humate-P® was rated as "excellent/good" in all 109 patients (100%) with VWD types 1 and 2
  • Humate-P® was rated as "excellent/good" in 198 of 208 patients (95%) with type 3 VWD—the most severe form

A US study involving 35 surgical patients with VWD and a European study involving 27 surgical patients with VWD assessed the safety and hemostatic efficacy of Humate-P® 24 hours after the last Humate-P® infusion or 14 days after surgery, whichever came earlier. Assessment of hemostatic efficacy showed:

  • Investigators rated efficacy as "excellent/good" for all 35 surgical subjects (100%) in the US study. The study was later reviewed by an independent Data Safety Monitoring Board (DSMB), which agreed with investigators' assessments of the overall hemostatic efficacy for all but two subjects (neither of whom had type 3 VWD); the DSMB judged hemostatic efficacy as "excellent/good" in 33 (94.3%) of the 35 subjects
  • Investigators rated efficacy as "excellent/good" for 26 of 27 surgical subjects (96.3%) in the European study

Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized, Humate-P® is indicated in adult patients for treatment and prevention of bleeding in hemophilia A (classical hemophilia). Humate-P® is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.

Humate-P® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations, or to any of its components.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.

Humate-P® is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most common adverse reactions reported in patients receiving Humate-P® are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References

  1. Lillicrap D, Poon M-C, Walker I, Xie F, Schwartz BA, and members of the Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002;87:224-230.